Skip to content

Our model for value creation

Home > Integrated annual report 2023/2024 > Our model for value creation

Our model for value creation

Financial resources

  • Reinvesting all profits in Group development
  • Nearly 20% of revenue from brand-name medicines invested in R&D each year to benefit patients

Intellectual capital

  • Nearly 7,000 valid patents (at February 2024), almost 70% of which in oncology
  • From 2023 to 2024: 7 PCT1 filings and 14 priority filings
  • 3rd most innovative pharmaceutical company in oncology in France2

(1) The Patent Cooperation Treaty (PCT) facilitates the procedure to obtain patent protection internationally.
(2) “Patents and innovation against cancer. Evidence from patent and company data”, European Patent Office, February 2024, epo.org.

R&D resources

  • 6 R&D centers
  • 3 hubs (North and South America, Europe, Asia-Pacific) and 15 clinical development centers
  • 58 R&D projects in the pipeline (December 2024)

Industrial resources

  • 14 production sites, including:
    • 2 chemical production facilities
    • 8 pharmaceutical production facilities for brand-name medicines
    • 4 production facilities for generic medicines

Human resources

  • Over 22,000 employees (at September 30, 2024), of which 22% based in France
  • Gender balance in the Group:
    • 57% women
    • 43% men (2024)
    • 48% of managers in the Servier Group are women

Environmental capital

  • 50% of our industrial facilities are certified ISO 50001 or ISO 14001:
    • Bolbec & Gidy (France),
    • Arklow (Irland),
    • Anpharm (Poland),
    • Toledo (Spain),
    • Cairo (Egypt),
    • Sophyno (Russia),
    • Tianjin (China).
  • One third of sites are also certified ISO 45001:
    • Arklow (Irland),
    • Toledo (Spain),
    • Cairo (Egypt),
    • Sophyno (Russia)

Environmental capital

Over 60 active scientific partnerships and collaborations

Number of projects ongoing with patient organizations: 250 (September 2024)

Financial

2023-2024 Group revenue: €5.9 bn

  • 2023-2024 EBITDA: €1.32 m (22.2% of revenue)

Scientific and therapeutic

29 brand-name medicines

  • A wide range of generic medicines distributed in France, Brazil and Eastern Europe
  • Nearly 140 countries where Group medicines are distributed
  • 1.3 billion boxes of medicines distributed throughout the world
  • Nearly 96% of the volume of active ingredients used in the Group’s brand-name medicines are produced by Servier in France
  • Ranked 3rd by oncology patient organizations3
  • Ranked top in three categories:
  • “Transparency on Data”,
  • “Beyond the Pill”, and “R&D”
  • 11th best company ranked by patient organizations that work with Servier3 (up 3 places on 2022)
  • Ranked top in 12 out of 14 categories compiled by US-based patient organizations that know Servier

(3) 2023 Ranking of pharmaceutical companies by reputation following the PatientView survey of patient organizations throughout the world.

Social

Servier was ranked 2nd in the Happy Trainees World ranking for the third consecutive year, also ranked 1st in France

  • 1st French company to receive the 2024 Gallup Exceptional Workplace Award
  • 22 of the Group’s subsidiaries certified Great Place to Work in 2023
  • Silver Brandon Hall Award (Best Corporate Learning University category) for the Servier & U corporate university
  • Deployment of D&I training for 100% of managers
  • 67% employee engagement within the Group4 (up 1 point on last year)

(4) Annual engagement survey conducted with the independent Gallup Institute – 2023 results

Environnemental

5% reduction in greenhouse gas emissions (across scopes 1 and 2) compared with 2022-2023

  • 19% renewable energy in the Group’s global energy mix (up 11 points on 2022-2023)
  • 5 sites fully powered by renewable energy
  • Integration of ecodesign principles for packaging by 2025

Sponsorship and solidarity

22 non-profit organizations received financial donations through the Mécénat Servier Charity Fund in 2023-2024

  • Nearly 3,000 hours of skill-based sponsorship completed in 2023-2024 by Group employees
  • Nearly €55,000 collected from employees in France rounding down their salary and Mécénat Servier matching their donations
  • 31 countries in which Mécénat Servier is active
  • Mobilization of Mécénat Servier in response to emergencies, in particular in Morocco, Brazil and Ukraine

Innovate

An independent Group with a long-term vision enabled by its governance model led by a non-profit foundation, the Fondation Internationale de Recherche Servier.

Vocation

Committed to therapeutic progress to serve patient needs

Our vision

Founded to serve health, our Group aspires to make a meaningful social impact for patients and for a sustainable world

2030 Ambition

  • Be an innovative and patient-driven business with a rich pipeline
  • Be a resilient, growing and highly profitable company balanced on its therapeutic areas
  • Be a business that creates a measurable positive social impact
  • Be an attractive company, for which its employees are proud and passionate to work

Therapeutic areas

  • Oncology
  • Cardiometabolism and venous diseases
  • Neurology
  • Immuno-inflammation
Previous page Ethics and compliance at the heart of the Group
Next page Key trends for our business